Format

Send to

Choose Destination
FASEB J. 2019 Feb 13:fj201801969RR. doi: 10.1096/fj.201801969RR. [Epub ahead of print]

A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice.

Author information

1
Department of Pulmonary Medicine, Aarhus University Hospital, Aarhus, Denmark.
2
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
3
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
4
Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.
5
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.

Abstract

Inhibitors of the activin receptor signaling pathway (IASPs) have become candidate therapeutics for sarcopenia and bone remodeling disorders because of their ability to increase muscle and bone mass. However, IASPs utilizing activin type IIA and IIB receptors are also potent stimulators of erythropoiesis, a feature that may restrict their usage to anemic patients because of increased risk of venous thromboembolism. Based on the endogenous TGF-β superfamily antagonist follistatin (FST), a molecule in the IASP class, FSTΔHBS-mFc, was generated and tested in both ovariectomized and naive BALB/c and C57BL/6 mice. In ovariectomized mice, FSTΔHBS-mFc therapy dose-dependently increased cancellous bone mass up to 42% and improved bone microstructural indices. For the highest dosage of FSTΔHBS-mFc (30 mg/kg, two times per week), the increase in cancellous bone mass was similar to that observed with parathyroid hormone therapy (1-34, 80 µg/kg, 5 times/wk). Musculus quadriceps femoris mass dose-dependently increased up to 21% in ovariectomized mice. In both ovariectomized and naive mice, FSTΔHBS-mFc therapy did not influence red blood cell count or hematocrit or hemoglobin levels. If the results are reproduced, a human FSTΔHBS-mFc version could be applicable in patients with musculoskeletal conditions irrespective of hematocrit status.-Lodberg, A., van der Eerden, B. C. J., Boers-Sijmons, B., Thomsen, J. S., Brüel, A., van Leeuwen, J. P. T. M., Eijken, M. A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice.

KEYWORDS:

IASP; erythropoiesis; muscle anabolic; osteoporosis; therapeutic

PMID:
30759349
DOI:
10.1096/fj.201801969RR

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center